Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPECS: Neoadjuvant Cemiplimab and Cetuximab in Locally Advanced Cutaneous Squamous Cell Carcinoma
NCT06418724Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and KL-140 in cutaneous squamous cell carcinoma (cSCC). Primary endpoint: Clinical downstaging rate to resectable status at 3 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cemiplimabKL-140
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT06418724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418724.